Fisher & Paykel Healthcare Corporation Limited has changed its admission category on the ASX to ASX Foreign Exempt Listing, effective from 20 June 2016.
The ASX Foreign Exempt Listing category is based on a principle of substituted compliance, with the primary regulatory role and oversight resting with the home exchange. Fisher & Paykel Healthcare continues to have a full listing on the NZX Main Board and the company’s shares will continue to be listed on ASX and included in all ASX indices as they are today.
Fisher & Paykel Healthcare remains committed to best practice in corporate governance, including guidelines of the NZX, ASX and the New Zealand Financial Markets Authority.
Contact: Marcus Driller, Investor Relations and Corporate Affairs Manager, on +64 9 574 0110. For more information about the company visit our website www.fphcare.com.
Fisher & Paykel Healthcare adopts ASX Foreign Exempt Listing
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
The heating and humidifying of respiratory gases is crucial for intubated patients. Learn about humidification devices, including active and passive.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Noninvasive respiratory support that provides a continuous distending pressure
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment